
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options. IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by our two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease
Isomab ltd operates in the Biotechnology research industry.
Isomab ltd's revenue is 11m - 100m
Isomab ltd has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.